Nuvation Bio Inc Ordinary Shares - Class A NUVB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in TKI-Naïve Advanced ROS1-Positive Non-Small Cell Lung Cancer
-
Nuvation Bio Announces New Analyses Reinforcing the Durable, Consistent Efficacy of IBTROZI® (taletrectinib) Across Key Patient Subgroups in Advanced ROS1+ NSCLC at 2026 World Conference on Lung Cancer
-
Nuvation Bio to Participate in Upcoming Investor Conferences
-
Nuvation Bio Granted FDA Fast-Track Designation for Glioma Treatment
-
Nuvation Bio Granted FDA Fast Track Designation for Safusidenib for Treatment of IDH1-Mutant Glioma
-
Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
-
Nuvation Bio to Present New Subgroup Analyses of Pivotal Data for IBTROZI® (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses
-
Nuvation Bio to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026
Trading Information
- Previous Close Price
- $4.75
- Day Range
- $4.42–4.76
- 52-Week Range
- $3.36–9.75
- Bid/Ask
- $4.33 / $4.55
- Shares Outstanding
- 351.12M
- Market Cap
- $1.56B
- Volume/Avg
- 4M / 6M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 9.60
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 305
- Website
- https://www.nuvationbio.com
Valuation
|
Metric
|
NUVB
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 6.50 |
Price/Sales | 9.60 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
NUVB
|
|---|---|
Quick Ratio | 7.98 |
Current Ratio | 8.37 |
Interest Coverage | −5.41 |
Quick Ratio
NUVB
Profitability
|
Metric
|
NUVB
|
|---|---|
Return on Assets (Normalized) | −16.94% |
Return on Equity (Normalized) | −34.33% |
Return on Invested Capital (Normalized) | −24.93% |
Return on Assets
NUVB
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|pm!Ybk | LOCK|DxZ> | $127B | |||
| Moderna Inc
MRNA
| LOCK|Z<%DPN | LOCK|Yv | $87B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|wS&>wt | LOCK|b>xfX | $81B | |||
| argenx SE ADR
ARGX
| LOCK|>h#ZLr | LOCK|tZ | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|R<Qv%^ | LOCK|dV | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|n&TSCB> | LOCK|P$!M@ | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|mb<RKpT< | LOCK|!gf$ | $27B | |||
| Incyte Corp
INCY
| LOCK|>>H#Y! | LOCK|$L | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|rY^<$! | LOCK|p$ | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|%<cW@K | LOCK|QMh | $14B |
United States